Predicting the efficacy of STN-DBS in patients with different Parkinson’s disease motor subtypes by preoperative total and partial levodopa response
Objective: To better investigate the value of the challenge test by introducing total and partial LR, and explain the clinical significance of 30% LR through…Kinetic Sensors for Ambulatory Gait and Balance Evaluation in Parkinson’s Disease
Objective: To explore the applicability of an ambulatory inertial sensor (G-walk) to characterize gait function during the Timed Up and Go (TUG) Test. Background: In…The Huntington’s Disease-Behavioral Questionnaire (HD-BQ): A New Screening Tool for Behavioral Disturbances in HD
Objective: To examine the usefulness of a new behavioral questionnaire for patients with, and at risk for, Huntington’s disease (HD). Background: Behavioral changes, including apathy,…Exploring the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD
Objective: To assess the effects of intrastriatal AAV5-miHTT therapy on MRS signal and mutant huntingtin levels in the Q175FDN mouse model of HD. Background: Huntingtin…Factors underlying reduced aerobic capacity in Huntington disease
Objective: Examine factors underlying aerobic capacity in prodromal and manifest Huntington disease (HD) and matched controls Background: HD results in motor impairments, weight loss, muscle…The effect of levodopa-carbidopa intestinal gel relative to optimized medical treatment on dyskinesia: Design and baseline characteristics for an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients (DYSCOVER Study)
Objective: The DYSCOVER study will be the first interventional, randomized study to evaluate the comparative effectiveness of levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment…Availability of Parkinson’s disease medicines in Ghana: a national survey
Objective: To determine the affordability, availability, geographic distribution and financing options of Parkinson’s disease (PD) medication in Ghana. Background: In sub-Saharan Africa, patients with PD…Safety of Iron Chelation in Patients with Brain Iron Overload
Objective: To assess the safety of iron chelation in the treatment of regional brain iron overload. Background: Excess brain iron is evident in neurodegenerative diseases…Changes to Speech Production after SpeechVive Treatment in Individuals with Parkinson’s Disease
Objective: The purpose of the present study was to assess the effects of a device-driven treatment (SpeechVive) on respiratory and laryngeal function after 8 weeks…Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease (PD) patients with persistent motor fluctuations: results of the 1-year open-label phase of the TOLEDO study
Objective: To evaluate the long-term safety and efficacy of apomorphine infusion (APO) in PD patients with motor fluctuations despite optimised oral therapy. Background: The randomised,…
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 217
- Next Page »